Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viridian Therapeutics, Inc. (Nasdaq: VRDN) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Viridian is a Waltham, Massachusetts-based biopharmaceutical company focused on antibody-based medicines for serious and rare diseases, including thyroid eye disease (TED) and autoimmune conditions involving IGF‑1R, TSHR, and FcRn pathways. Its common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC under the symbol VRDN, as noted in multiple Form 8‑K filings.
Through this page, users can review current and historical Forms 8‑K in which Viridian reports material events such as clinical and regulatory milestones, collaboration and license agreements, financing transactions, and governance matters. Examples disclosed in recent 8‑K filings include public equity offerings, a royalty financing agreement, an amended credit facility, and the collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. Other 8‑Ks furnish press releases reporting quarterly financial results and cash positions, providing insight into the company’s operating expenses, research and development investments, and capital resources.
Investors can also use the filings page to track capital markets activity and share-related arrangements, such as underwriting agreements for public offerings, equity incentive plan amendments, and employee stock purchase plans, all of which appear in Viridian’s current reports and proxy-related disclosures. These documents outline how the company structures its financing, equity compensation, and shareholder approvals as it advances late-stage TED programs and its FcRn inhibitor portfolio.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that highlight the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly understand the main terms of material agreements, the significance of clinical and regulatory announcements, and the implications of financing transactions for Viridian’s runway and strategic plans. For deeper analysis, investors can drill down into specific filings—such as 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available—to examine risk factors, detailed financial statements, and any reported insider buying or selling activity related to VRDN.
Viridian Therapeutics reported a sharper top line in its Q3 2025 10-Q driven by license activity. Total revenue reached $70.6 million, including $70.0 million of license revenue. The company posted a net loss of $34.6 million, improving from a loss of $76.7 million a year ago, as higher revenue offset increased operating costs. Research and development expense was $86.3 million, and general and administrative expense was $24.3 million in the quarter.
Liquidity remains strong. Cash, cash equivalents and short-term investments totaled $490.9 million as of September 30, 2025, which management states should fund planned operations for at least twelve months. Year to date, net cash used in operating activities was $252.6 million, partly offset by $301.9 million net cash provided by investing activities and $20.8 million from financing. Long-term debt stood at $20.9 million, and in October 2025 the company extended its loan maturity to October 2030. Common shares outstanding were 95,442,008 as of October 31, 2025.
Viridian Therapeutics (VRDN) announced quarterly results by issuing a press release for the quarter ended September 30, 2025. The company furnished the release as Exhibit 99.1 under Item 2.02 of a Form 8-K.
The press release is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act and is not incorporated by reference into other filings. The report was signed by President and Chief Executive Officer Stephen Mahoney.
Viridian Therapeutics (VRDN) reported an insider purchase on a Form 4. On 10/23/2025, Fairmount Healthcare Fund II LP acquired 454,545 shares of common stock at $22 per share (transaction code P). Following the trade, the fund beneficially owned 3,914,458 shares, held indirectly.
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over the securities held by Fairmount Healthcare Fund II LP, and they disclaim beneficial ownership except to the extent of their pecuniary interest. The reporting persons are indicated as a Director and 10% Owner, and the form was filed by more than one reporting person.
Viridian Therapeutics (VRDN) announced an underwritten public offering of common stock. The company agreed to sell 11,425,000 shares at $22.00 per share, for aggregate gross proceeds of approximately $251.35 million before underwriting discounts, commissions, and expenses. Underwriters have a 30‑day option to purchase up to an additional 1,713,750 shares on the same terms. The offering was made under an automatically effective shelf registration statement and is expected to close on October 23, 2025.
Viridian states that the net proceeds, together with existing cash and other expected sources— including a $70 million upfront payment receivable from Kissei in the fourth quarter of 2025, the $55 million upfront payment from a purchase and sale agreement with DRI plus $115 million in potential near‑term milestones under that agreement, and $30 million from a term loan facility—should provide sufficient capital to fund currently anticipated operations. The company also references anticipated revenue from veligrotug and VRDN‑003 sales if each is approved on its anticipated timelines.
Viridian Therapeutics launched a primary offering of 11,425,000 shares of common stock at $22.00 per share. The deal implies a $251,350,000 gross raise, with underwriting fees of $15,081,000, for estimated net proceeds of $236,269,000 before expenses. Underwriters have a 30‑day option to purchase up to 1,713,750 additional shares.
The company plans to use proceeds, together with existing liquidity, to fund commercial launch activities for veligrotug and VRDN‑003, R&D, and for working capital and general corporate purposes.
Viridian noted preliminary cash, cash equivalents and marketable securities of $490.9 million as of September 30, 2025. Recent financing activities include a purchase and sale agreement with DRI providing up to $300 million in consideration, including $55 million received at signing, and an amended Hercules term loan facility of up to $300.0 million.
Nazdaq symbol: VRDN; settlement is expected on or about October 23, 2025.
Viridian Therapeutics (VRDN) launched a preliminary 424B5 for a primary offering of common stock and, in lieu of common for certain investors, Series B non-voting convertible preferred stock. Each Series B share converts into 66.67 shares of common at the holder’s election, subject to a holder‑set Beneficial Ownership Limitation between 4.9% and 19.9%. The company granted underwriters a 30‑day option to buy additional common shares. Net proceeds will support commercial launch activities for veligrotug and VRDN‑003, research and development, and general corporate purposes.
Viridian reported preliminary cash, cash equivalents and marketable securities of $490.9 million as of September 30, 2025. On October 17, 2025, it entered a Purchase and Sale Agreement with DRI for up to $300 million tied to clinical, regulatory and commercial milestones, with tiered U.S. net sales royalties of 7.5% up to $600 million, 0.8% from $600–$900 million, and 0.25% from $900 million–$2 billion. The same day, Viridian amended its Hercules facility to provide up to $300.0 million across tranches, maturing on October 17, 2030, with a floating rate capped at 9.45% and an interest‑only period through October 17, 2029 (extendable upon milestones). Common stock trades on Nasdaq as “VRDN”; Series B has no planned listing.
Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The figure is unaudited and subject to completion of financial closing procedures, and the company’s independent auditor has not performed any review or assurance work on this number. The final amount reported in the upcoming unaudited condensed consolidated balance sheet may differ materially.
Viridian Therapeutics, Inc. files an S-3ASR prospectus supplement describing its pipeline and offering mechanics. The company highlights lead programs including veligrotug (an intravenous anti-IGF-1R monoclonal antibody) and VRDN-003 (a planned low-volume, subcutaneous anti-IGF-1R intended for at-home auto-injector use for TED). The filing states VRDN-006 and VRDN-008 are engineered FcRn inhibitors. Stated timelines include VRDN-006 proof-of-concept IgG reduction data in Q3 2025, an anticipated IND submission for VRDN-008 by end of 2025, and anticipated VRDN-003 topline REVEAL-1 and REVEAL-2 data in H1 2026. As of September 3, 2025 the company had 81,668,033 common shares outstanding, 134,864 Series A and 145,160 Series B preferred shares. Use of proceeds is for development, commercialization preparation, working capital and general corporate purposes. The Registration Rights Agreement requires Viridian to use commercially reasonable efforts to register certain shares and explicitly does not include demand or piggyback registration rights.